294 related articles for article (PubMed ID: 36546659)
1. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated
Yaeger R; Weiss J; Pelster MS; Spira AI; Barve M; Ou SI; Leal TA; Bekaii-Saab TS; Paweletz CP; Heavey GA; Christensen JG; Velastegui K; Kheoh T; Der-Torossian H; Klempner SJ
N Engl J Med; 2023 Jan; 388(1):44-54. PubMed ID: 36546659
[TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
[TBL] [Abstract][Full Text] [Related]
3. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
[TBL] [Abstract][Full Text] [Related]
4. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated
Fakih MG; Salvatore L; Esaki T; Modest DP; Lopez-Bravo DP; Taieb J; Karamouzis MV; Ruiz-Garcia E; Kim TW; Kuboki Y; Meriggi F; Cunningham D; Yeh KH; Chan E; Chao J; Saportas Y; Tran Q; Cremolini C; Pietrantonio F
N Engl J Med; 2023 Dec; 389(23):2125-2139. PubMed ID: 37870968
[TBL] [Abstract][Full Text] [Related]
5. Adagrasib in Advanced Solid Tumors Harboring a
Bekaii-Saab TS; Yaeger R; Spira AI; Pelster MS; Sabari JK; Hafez N; Barve M; Velastegui K; Yan X; Shetty A; Der-Torossian H; Pant S
J Clin Oncol; 2023 Sep; 41(25):4097-4106. PubMed ID: 37099736
[TBL] [Abstract][Full Text] [Related]
6. Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With
Negrao MV; Spira AI; Heist RS; Jänne PA; Pacheco JM; Weiss J; Gadgeel SM; Velastegui K; Yang W; Der-Torossian H; Christensen JG; Sabari JK
J Clin Oncol; 2023 Oct; 41(28):4472-4477. PubMed ID: 37327468
[No Abstract] [Full Text] [Related]
7. A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer.
Segal NH; Gada P; Senzer N; Gargano MA; Patchen ML; Saltz LB
Clin Colorectal Cancer; 2016 Sep; 15(3):222-7. PubMed ID: 26975418
[TBL] [Abstract][Full Text] [Related]
8. Sotorasib for previously treated colorectal cancers with KRAS
Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
[TBL] [Abstract][Full Text] [Related]
9. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
10. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
11. Sotorasib with panitumumab in chemotherapy-refractory KRAS
Kuboki Y; Fakih M; Strickler J; Yaeger R; Masuishi T; Kim EJ; Bestvina CM; Kopetz S; Falchook GS; Langer C; Krauss J; Puri S; Cardona P; Chan E; Varrieur T; Mukundan L; Anderson A; Tran Q; Hong DS
Nat Med; 2024 Jan; 30(1):265-270. PubMed ID: 38177853
[TBL] [Abstract][Full Text] [Related]
12. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
13. Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J; Alonso G; Kim SH; Cervantes A; Karasic T; Medina L; Shacham-Shmueli E; Cosman R; Falcon A; Gort E; Guren T; Massarelli E; Miller WH; Paz-Ares L; Prenen H; Amatu A; Cremolini C; Kim TW; Moreno V; Ou SI; Passardi A; Sacher A; Santoro A; Stec R; Ulahannan S; Arbour K; Lorusso P; Luo J; Patel MR; Choi Y; Shi Z; Mandlekar S; Lin MT; Royer-Joo S; Chang J; Jun T; Dharia NV; Schutzman JL; ; Han SW
Nat Med; 2024 Jan; 30(1):271-278. PubMed ID: 38052910
[TBL] [Abstract][Full Text] [Related]
14. Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract][Full Text] [Related]
15. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A
JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468
[TBL] [Abstract][Full Text] [Related]
16. Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.
Segelov E; Thavaneswaran S; Waring PM; Desai J; Robledo KP; Gebski VJ; Elez E; Nott LM; Karapetis CS; Lunke S; Chantrill LA; Pavlakis N; Khasraw M; Underhill C; Ciardiello F; Jefford M; Wasan H; Haydon A; Price TJ; van Hazel G; Wilson K; Simes J; Shapiro JD
J Clin Oncol; 2016 Jul; 34(19):2258-64. PubMed ID: 27114605
[TBL] [Abstract][Full Text] [Related]
17. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
18. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
19. KRAS
Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Martinelli E; Martini G; Famiglietti V; Troiani T; Napolitano S; Pietrantonio F; Ciardiello D; Terminiello M; Borrelli C; Vitiello PP; De Braud F; Morano F; Avallone A; Normanno N; Nappi A; Maiello E; Latiano T; Falcone A; Cremolini C; Rossini D; Santabarbara G; Pinto C; Santini D; Cardone C; Zanaletti N; Di Liello A; Renato D; Esposito L; Marrone F; Ciardiello F
JAMA Oncol; 2021 Oct; 7(10):1529-1535. PubMed ID: 34382998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
